Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
Open Access
- 8 March 2024
- journal article
- review article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (3) , 102064
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancerCancer Chemotherapy and Pharmacology, 2022
- Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancerInternational Journal of Cancer, 2021
- Therapeutic drug monitoring of oral targeted antineoplastic drugsEuropean Journal of Clinical Pharmacology, 2020
- Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinomaInternational Journal of Clinical Oncology, 2018
- Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimizationCancer Chemotherapy and Pharmacology, 2017
- Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringCancer Chemotherapy and Pharmacology, 2017
- Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated CancerCPT: Pharmacometrics & Systems Pharmacology, 2017
- Therapeutic drug monitoring for tomorrowEuropean Journal of Clinical Pharmacology, 2013
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic AnalysisThe Journal of Clinical Pharmacology, 2013
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009